SMi Systems has disclosed a £6m ($7.6m) seed funding round to develop and prove the utility of its multi-omic platform for in vitro diagnosis and biomedical research.
SMi hopes the technology will significantly accelerate the discovery of new therapeutics by biopharma companies and research institutions.
The company has also hired a new Chief Development Officer (CDO) experienced in product commercialisation, Dr Michael Risley.
The new platform is underpinned by SMi’s super-resolution optical technology that provides high spatial (1.6 nanometre) and temporal (0.5 millisecond) resolution. Coupled with AI, the platform is designed to deliver unprecedented quantification of single molecules associated with diseases and those used to develop new therapeutics.
Dr Andrew Thompson, Chief Executive Officer (CEO) at SMi, said: “With the significant investment we’ve received and the appointment of Michael as CDO, we’re building a strong foundation for us to continue developing our products and accelerate their implementation for a vast range of applications, from disease diagnosis to drug and vaccine discovery.”
